Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer
Shots:
- Merus & Partner Therapeutics have signed a licensing agreement for commercializing zenocutuzumab to treat NRG1+ cancer across the US. A BLA is under review for previously treated NRG1+ NSCLC & pancreatic cancer in the US
- As per the agreement, Merus is eligible for an upfront, milestones & high single-digit to low double-digit annual net-sales based royalties in exchange for the US commercialization rights to zenocutuzumab post transition period
- Zeno, a Biclonics using the Merus Dock & Block mechanism, targets the neuregulin/HER3 pathway in NRG1+ solid tumors. By binding to HER2 and blocking HER3-NRG1 interactions, it shows strong potential against NRG1+ cancers
Ref: Merus | Image: Merus & Partner Therapeutics
Related News:- Silo Pharma and Kymanox Join Forces for SP-26 Ketamine Implant Device Targeting Pain Management
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
